A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS)

Trial Profile

A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS)

Suspended
Phase of Trial: Phase I/II

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Vadastuximab talirine (Primary) ; Azacitidine; Azacitidine
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 19 Jun 2017 According to a company media release, Seattle Genetics is suspending patient enrollment and treatment in all of its vadastuximab talirine clinical trials based on unfavourable results obtained in the phase III CASCADE trial.
    • 19 Jun 2017 Status changed from recruiting to suspended according to a Seattle Genetics media release.
    • 26 Apr 2017 Planned number of patients changed from 130 to 142.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top